RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform. The company's goal is to improve therapeutic outcomes for cancer patients undergoing treatment by ensuring precise therapeutic delivery to directly target the tumor while potentially minimizing the therapy's toxicities versus systemic (intravenous (IV) therapy). RenovoRx's unique approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy.